Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

Open Access 01-01-2016 | Original Article

Downregulation of DHRS9 expression in colorectal cancer tissues and its prognostic significance

Authors: Liang Hu, Hai-Yang Chen, Tao Han, Guang-Zhen Yang, Dan Feng, Chen-Ye Qi, Hui Gong, Yan-Xia Zhai, Qing-Ping Cai, Chun-Fang Gao

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

Dehydrogenase/reductase (SDR family) member 9 (DHRS9) is aberrantly expressed in colorectal cancer (CRC), but its prognostic value is unknown. The aim of the work was to investigate the prognostic significance of DHRS9 expression in CRC. We found that DHRS9 was frequently downregulated in CRC clinical samples at both the messenger RNA (mRNA) and protein levels. Decreased expression of DHRS9 was significantly correlated with increased lymph node metastasis (p = 0.032), advanced tumor–node–metastasis (TNM) stage (p = 0.021), increased disease recurrence (p = 0.001), and death (p = 0.014). Kaplan–Meier analysis indicated that low DHRS9 expression predicted poor disease-free survival (p = 0.003) and disease-specific survival (p = 0.021). Cox multivariate analysis revealed that reduced expression of DHRS9 was an independent unfavorable prognostic indicator for CRC. Furthermore, combination of DHRS9 with TNM stage was a more powerful predictor of poor prognosis than either of the two parameters alone. Our results suggest that decreased expression of DHRS9 correlates with tumor progression and may serve as a potential prognostic biomarker in CRC.
Literature
1.
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
3.
Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18:1688–94.CrossRefPubMed
4.
Zheng ZX, Zheng RS, Zhang SW, Chen WQ. Colorectal cancer incidence and mortality in China, 2010. Asian Pac J Cancer Prev. 2014;15:8455–60.CrossRefPubMed
5.
Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.CrossRefPubMed
6.
Bosetti C, Bertuccio P, Malvezzi M, et al. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol. 2013;24:2657–71.CrossRefPubMed
7.
Chatenoud L, Bertuccio P, Bosetti C, et al. Trends in mortality from major cancers in the Americas: 1980–2010. Ann Oncol. 2014;25:1843–53.CrossRefPubMed
8.
Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73.CrossRefPubMedPubMedCentral
9.
Jones RJ, Dickerson S, Bhende PM, et al. Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9. J Biol Chem. 2007;282:8317–24.CrossRefPubMed
10.
Kropotova ES, Zinovieva OL, Zyryanova AF, et al. Altered expression of multiple genes involved in retinoic acid biosynthesis in human colorectal cancer. Pathol Oncol Res. 2014;20:707–17.CrossRefPubMed
11.
Wang C, Kane MA, Napoli JL. Multiple retinol and retinal dehydrogenases catalyze all-trans-retinoic acid biosynthesis in astrocytes. J Biol Chem. 2011;286:6542–53.CrossRefPubMed
12.
13.
Napoli JL. Physiological insights into all-trans-retinoic acid biosynthesis. Biochim Biophys Acta. 1821;2012:152–67.
14.
Soref CM, Di YP, Hayden L, et al. Characterization of a novel airway epithelial cell-specific short chain alcohol dehydrogenase/reductase gene whose expression is up-regulated by retinoids and is involved in the metabolism of retinol. J Biol Chem. 2001;276:24194–202.CrossRefPubMed
15.
Jette C, Peterson PW, Sandoval IT, et al. The tumor suppressor adenomatous polyposis coli and caudal related homeodomain protein regulate expression of retinol dehydrogenase L. J Biol Chem. 2004;279:34397–405.CrossRefPubMed
16.
17.
Hu L, Chen L, Yang G, et al. HBx sensitizes cells to oxidative stress-induced apoptosis by accelerating the loss of Mcl-1 protein via caspase-3 cascade. Mol Cancer. 2011;10:43.CrossRefPubMedPubMedCentral
18.
Wang RY, Chen L, Chen HY, et al. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients. Gastroenterology. 2013;145:1436–48. e1431-1412.CrossRefPubMed
19.
Tang L, Tan YX, Jiang BG, et al. The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma. Clin Cancer Res. 2013;19:2014–24.CrossRefPubMed
20.
Li W, Yu CP, Xia JT, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2009;15:1393–9.CrossRefPubMed
21.
Liu N, Cui RX, He QM, et al. Reduced expression of Dicer11 is associated with poor prognosis in patients with nasopharyngeal carcinoma. Med Oncol. 2013;30:360.CrossRefPubMed
22.
Young MJ, Wu YH, Chiu WT et al. All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells. Carcinogenesis 2015.
23.
Li B, Gao MH, Chu XM, et al. The synergistic antitumor effects of all-trans retinoic acid and C-phycocyanin on the lung cancer A549 cells in vitro and in vivo. Eur J Pharmacol. 2015;749:107–14.CrossRefPubMed
24.
Niles RM, Wilhelm SA, Thomas P, Zamcheck N. The effect of sodium butyrate and retinoic acid on growth and CEA production in a series of human colorectal tumor cell lines representing different states of differentiation. Cancer Investig. 1988;6:39–45.CrossRef
25.
Reynolds S, Rajagopal S, Chakrabarty S. Differentiation-inducing effect of retinoic acid, difluoromethylornithine, sodium butyrate and sodium suramin in human colon cancer cells. Cancer Lett. 1998;134:53–60.CrossRefPubMed
26.
Adachi Y, Itoh F, Yamamoto H, et al. Retinoic acids reduce matrilysin (matrix metalloproteinase 7) and inhibit tumor cell invasion in human colon cancer. Tumour Biol. 2001;22:247–53.CrossRefPubMed
27.
Nicke B, Kaiser A, Wiedenmann B, et al. Retinoic acid receptor alpha mediates growth inhibition by retinoids in human colon carcinoma HT29 cells. Biochem Biophys Res Commun. 1999;261:572–7.CrossRefPubMed
28.
Pasquali D, Thaller C, Eichele G. Abnormal level of retinoic acid in prostate cancer tissues. J Clin Endocrinol Metab. 1996;81:2186–91.PubMed
29.
Mira YLR, Zheng WL, Kuppumbatti YS, et al. Retinol conversion to retinoic acid is impaired in breast cancer cell lines relative to normal cells. J Cell Physiol. 2000;185:302–9.CrossRef
30.
Williams SJ, Cvetkovic D, Hamilton TC. Vitamin A metabolism is impaired in human ovarian cancer. Gynecol Oncol. 2009;112:637–45.CrossRefPubMed
31.
Matsumoto M, Yokoyama H, Suzuki H, et al. Retinoic acid formation from retinol in the human gastric mucosa: role of class IV alcohol dehydrogenase and its relevance to morphological changes. Am J Physiol Gastrointest Liver Physiol. 2005;289:G429–433.CrossRefPubMed
32.
Pares X, Farres J, Kedishvili N, Duester G. Medium- and short-chain dehydrogenase/reductase gene and protein families : medium-chain and short-chain dehydrogenases/reductases in retinoid metabolism. Cell Mol Life Sci. 2008;65:3936–49.CrossRefPubMedPubMedCentral
33.
Wang J, Peng Y, Sun YW, et al. All-trans retinoic acid induces XAF1 expression through an interferon regulatory factor-1 element in colon cancer. Gastroenterology. 2006;130:747–58.CrossRefPubMed
34.
Woo YJ, Jang KL. All-trans retinoic acid activates E-cadherin expression via promoter hypomethylation in the human colon carcinoma HCT116 cells. Biochem Biophys Res Commun. 2012;425:944–9.CrossRefPubMed
35.
Webber C, Gospodarowicz M, Sobin LH, et al. Improving the TNM classification: findings from a 10-year continuous literature review. Int J Cancer. 2014;135:371–8.CrossRefPubMed
Metadata
Title
Downregulation of DHRS9 expression in colorectal cancer tissues and its prognostic significance
Authors
Liang Hu
Hai-Yang Chen
Tao Han
Guang-Zhen Yang
Dan Feng
Chen-Ye Qi
Hui Gong
Yan-Xia Zhai
Qing-Ping Cai
Chun-Fang Gao
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3880-6

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Original Article

MiR-375 targets KLF4 and impacts the proliferation of colorectal carcinoma

Research Article

The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma

Research Article

The ubiquitin ligase RNF43 downregulation increases membrane expression of frizzled receptor in pancreatic ductal adenocarcinoma

Original Article

Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma

Review

IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma

Original Article

CCL18 promotes the invasion and migration of gastric cancer cells via ERK1/2/NF-κB signaling pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits